RxDoctor Payments Data

Amanda Fischbein

Adult Health · West Columbia, SCNPI 1093465759

Payments from drug & device makers

$3,343in general payments, 2019–2025

Across 80 payments — averaging $41.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Altathera Pharmaceuticals LLC$1K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$635
  • AstraZeneca$315
  • E.r. Squibb & Sons, L.L.C.$291
  • Boston Scientific$202
  • Novartis$129
  • plus $754 from 19 others

What the payments were for

  • Speaking & faculty fees$1,00030%
  • Food & beverage$2,28068%
  • Education$632%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,343 in reported general payments places this provider in the 75th percentile of 292 adult health providers in South Carolina.

See all adult health providers in South Carolina

Medicare billing

Part B allowed, 2024
$5,758
Medicare patients
72
Services billed
98

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban582$530,322
XareltoRivaroxaban82$91,161
EntrestoSacubitril/Valsartan52$53,206
MultaqDronedarone Hcl11$15,034
FarxigaDapagliflozin Propanediol12$11,251
Dofetilide35$6,189
Metoprolol Succinate384$5,786
Diltiazem 24hr Er (Cd)Diltiazem Hcl127$5,435
Flecainide Acetate89$4,055
Amiodarone Hcl124$2,043
SotalolSotalol Hcl101$1,947
Rosuvastatin Calcium68$1,640
ClopidogrelClopidogrel Bisulfate96$1,440
Atorvastatin Calcium111$1,223
Valsartan30$1,142

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$40$530,322582 claims
NovartisEntresto$129$53,20652 claims
Sanofi-aventis U.S. LLCMultaq$21$15,03411 claims
AstraZenecaFarxiga$315$11,25112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 292 adult health providers in South Carolina.

Other adult health in West Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →